MAGNUSON TERRY 4

Accession 0001181158-11-000004

CIK 0001003124other

Filed

Dec 5, 7:00 PM ET

Accepted

Dec 6, 9:17 AM ET

Size

28.7 KB

Accession

0001181158-11-000004

Form 4

Period: 2011-12-05

Director

Transactions

Disposition to Issuer
Stock Options (to buy)
2011-12-05−9,090→ 0 total
Exercise: $24.26→ 9090 (9,090 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−4,113→ 0 total
Exercise: $34.18→ Common Stock (4,113 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−5,650→ 0 total
Exercise: $22.98→ Common Stock (5,650 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−16,561→ 0 total
Exercise: $15.28→ Common Stock (16,561 underlying)
Disposition to Issuer
Common Stock
2011-12-05$33.25/sh−17,633$586,297→ 0 total
Disposition to Issuer
Stock Options (to buy)
2011-12-05−10,496→ 0 total
Exercise: $24.52→ Common Stock (10,496 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−6,485→ 0 total
Exercise: $41.32→ Common Stock (6,485 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−6,341→ 0 total
Exercise: $32.67→ Common Stock (6,341 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−16,561→ 0 total
Exercise: $13.12→ Common Stock (16,561 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−9,095→ 0 total
Exercise: $28.52→ Common Stock (9,095 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−14,053→ 0 total
Exercise: $19.19→ Common Stock (14,053 underlying)
Disposition to Issuer
Stock Options (to buy)
2011-12-05−12,421→ 0 total
Exercise: $12.37→ Common Stock (12,421 underlying)

Footnotes (3)

[F1]Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
[F2]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 7/30/2011, 7/30/2012 and 7/30/2013 but vesting was accelerated due to the Merger.
[F3]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.

Documents

1 file

PHARMACEUTICAL PRODUCT DEVELOPMENT INC

CIK 0001003124

Entity typeother